Fabry disease: Polymorphic haplotypes and a novel missense mutation in the GLA gene

L. Ferri, C. Guido, G. la Marca, S. Malvagia, C. Cavicchi, A. Fiumara, R. Barone, R. Parini, D. Antuzzi, C. Feliciani, A. Zampetti, R. Manna, S. Giglio, C. M. Della Valle, X. Wu, K. J. Valenzano, E. R. Benjamin, M. A. Donati, R. Guerrini, M. GenuardiA. Morrone

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene. Fabry disease (FD) is an X-linked lysosomal storage disorder with a heterogeneous spectrum of clinical manifestations that are caused by the deficiency of α-galactosidase A (α-Gal-A) activity. Although useful for diagnosis in males, enzyme activity is not a reliable biochemical marker in heterozygous females due to random X-chromosome inactivation, thus rendering DNA sequencing of the α-Gal-A gene, alpha-galactosidase gene (GLA), the most reliable test for the confirmation of diagnosis in females. The spectrum of GLA mutations is highly heterogeneous. Many polymorphic GLA variants have been described, but it is unclear if haplotypes formed by combinations of such variants correlate with FD, thus complicating molecular diagnosis in females with normal α-Gal-A activity. We tested 67 female probands with clinical manifestations that may be associated with FD and 110 control males with normal α-Gal-A activity. Five different combinations of GLA polymorphic variants were identified in 14 of the 67 females, whereas clearcut pathogenetic alterations, p.Met51Ile and p.Met290Leu, were identified in two cases. The latter has not been reported so far, and both mutant forms were found to be responsive to the pharmacological chaperone deoxygalactonojirimycin (DGJ; migalastat hydrochloride). Analysis of the male control population, as well as male relatives of a suspected FD female proband, permitted the identification of seven different GLA gene haplotypes in strong linkage disequilibrium. The identification of haplotypes in control males provides evidence against their involvement in the development of FD phenotypic manifestations.

Original languageEnglish
Pages (from-to)224-233
Number of pages10
JournalClinical Genetics
Volume81
Issue number3
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Galactosidases
Fabry Disease
Missense Mutation
Haplotypes
Genes
alpha-Galactosidase
X Chromosome Inactivation
Linkage Disequilibrium
DNA Sequence Analysis
Biomarkers
Pharmacology

Keywords

  • Fabry disease
  • GLA gene variants
  • Haplotypes
  • Polymorphism

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Ferri, L., Guido, C., la Marca, G., Malvagia, S., Cavicchi, C., Fiumara, A., ... Morrone, A. (2012). Fabry disease: Polymorphic haplotypes and a novel missense mutation in the GLA gene. Clinical Genetics, 81(3), 224-233. https://doi.org/10.1111/j.1399-0004.2011.01689.x

Fabry disease : Polymorphic haplotypes and a novel missense mutation in the GLA gene. / Ferri, L.; Guido, C.; la Marca, G.; Malvagia, S.; Cavicchi, C.; Fiumara, A.; Barone, R.; Parini, R.; Antuzzi, D.; Feliciani, C.; Zampetti, A.; Manna, R.; Giglio, S.; Della Valle, C. M.; Wu, X.; Valenzano, K. J.; Benjamin, E. R.; Donati, M. A.; Guerrini, R.; Genuardi, M.; Morrone, A.

In: Clinical Genetics, Vol. 81, No. 3, 03.2012, p. 224-233.

Research output: Contribution to journalArticle

Ferri, L, Guido, C, la Marca, G, Malvagia, S, Cavicchi, C, Fiumara, A, Barone, R, Parini, R, Antuzzi, D, Feliciani, C, Zampetti, A, Manna, R, Giglio, S, Della Valle, CM, Wu, X, Valenzano, KJ, Benjamin, ER, Donati, MA, Guerrini, R, Genuardi, M & Morrone, A 2012, 'Fabry disease: Polymorphic haplotypes and a novel missense mutation in the GLA gene', Clinical Genetics, vol. 81, no. 3, pp. 224-233. https://doi.org/10.1111/j.1399-0004.2011.01689.x
Ferri L, Guido C, la Marca G, Malvagia S, Cavicchi C, Fiumara A et al. Fabry disease: Polymorphic haplotypes and a novel missense mutation in the GLA gene. Clinical Genetics. 2012 Mar;81(3):224-233. https://doi.org/10.1111/j.1399-0004.2011.01689.x
Ferri, L. ; Guido, C. ; la Marca, G. ; Malvagia, S. ; Cavicchi, C. ; Fiumara, A. ; Barone, R. ; Parini, R. ; Antuzzi, D. ; Feliciani, C. ; Zampetti, A. ; Manna, R. ; Giglio, S. ; Della Valle, C. M. ; Wu, X. ; Valenzano, K. J. ; Benjamin, E. R. ; Donati, M. A. ; Guerrini, R. ; Genuardi, M. ; Morrone, A. / Fabry disease : Polymorphic haplotypes and a novel missense mutation in the GLA gene. In: Clinical Genetics. 2012 ; Vol. 81, No. 3. pp. 224-233.
@article{190352f5bede43a09819bbf2ce306aa0,
title = "Fabry disease: Polymorphic haplotypes and a novel missense mutation in the GLA gene",
abstract = "Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene. Fabry disease (FD) is an X-linked lysosomal storage disorder with a heterogeneous spectrum of clinical manifestations that are caused by the deficiency of α-galactosidase A (α-Gal-A) activity. Although useful for diagnosis in males, enzyme activity is not a reliable biochemical marker in heterozygous females due to random X-chromosome inactivation, thus rendering DNA sequencing of the α-Gal-A gene, alpha-galactosidase gene (GLA), the most reliable test for the confirmation of diagnosis in females. The spectrum of GLA mutations is highly heterogeneous. Many polymorphic GLA variants have been described, but it is unclear if haplotypes formed by combinations of such variants correlate with FD, thus complicating molecular diagnosis in females with normal α-Gal-A activity. We tested 67 female probands with clinical manifestations that may be associated with FD and 110 control males with normal α-Gal-A activity. Five different combinations of GLA polymorphic variants were identified in 14 of the 67 females, whereas clearcut pathogenetic alterations, p.Met51Ile and p.Met290Leu, were identified in two cases. The latter has not been reported so far, and both mutant forms were found to be responsive to the pharmacological chaperone deoxygalactonojirimycin (DGJ; migalastat hydrochloride). Analysis of the male control population, as well as male relatives of a suspected FD female proband, permitted the identification of seven different GLA gene haplotypes in strong linkage disequilibrium. The identification of haplotypes in control males provides evidence against their involvement in the development of FD phenotypic manifestations.",
keywords = "Fabry disease, GLA gene variants, Haplotypes, Polymorphism",
author = "L. Ferri and C. Guido and {la Marca}, G. and S. Malvagia and C. Cavicchi and A. Fiumara and R. Barone and R. Parini and D. Antuzzi and C. Feliciani and A. Zampetti and R. Manna and S. Giglio and {Della Valle}, {C. M.} and X. Wu and Valenzano, {K. J.} and Benjamin, {E. R.} and Donati, {M. A.} and R. Guerrini and M. Genuardi and A. Morrone",
year = "2012",
month = "3",
doi = "10.1111/j.1399-0004.2011.01689.x",
language = "English",
volume = "81",
pages = "224--233",
journal = "Clinical Genetics",
issn = "0009-9163",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "3",

}

TY - JOUR

T1 - Fabry disease

T2 - Polymorphic haplotypes and a novel missense mutation in the GLA gene

AU - Ferri, L.

AU - Guido, C.

AU - la Marca, G.

AU - Malvagia, S.

AU - Cavicchi, C.

AU - Fiumara, A.

AU - Barone, R.

AU - Parini, R.

AU - Antuzzi, D.

AU - Feliciani, C.

AU - Zampetti, A.

AU - Manna, R.

AU - Giglio, S.

AU - Della Valle, C. M.

AU - Wu, X.

AU - Valenzano, K. J.

AU - Benjamin, E. R.

AU - Donati, M. A.

AU - Guerrini, R.

AU - Genuardi, M.

AU - Morrone, A.

PY - 2012/3

Y1 - 2012/3

N2 - Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene. Fabry disease (FD) is an X-linked lysosomal storage disorder with a heterogeneous spectrum of clinical manifestations that are caused by the deficiency of α-galactosidase A (α-Gal-A) activity. Although useful for diagnosis in males, enzyme activity is not a reliable biochemical marker in heterozygous females due to random X-chromosome inactivation, thus rendering DNA sequencing of the α-Gal-A gene, alpha-galactosidase gene (GLA), the most reliable test for the confirmation of diagnosis in females. The spectrum of GLA mutations is highly heterogeneous. Many polymorphic GLA variants have been described, but it is unclear if haplotypes formed by combinations of such variants correlate with FD, thus complicating molecular diagnosis in females with normal α-Gal-A activity. We tested 67 female probands with clinical manifestations that may be associated with FD and 110 control males with normal α-Gal-A activity. Five different combinations of GLA polymorphic variants were identified in 14 of the 67 females, whereas clearcut pathogenetic alterations, p.Met51Ile and p.Met290Leu, were identified in two cases. The latter has not been reported so far, and both mutant forms were found to be responsive to the pharmacological chaperone deoxygalactonojirimycin (DGJ; migalastat hydrochloride). Analysis of the male control population, as well as male relatives of a suspected FD female proband, permitted the identification of seven different GLA gene haplotypes in strong linkage disequilibrium. The identification of haplotypes in control males provides evidence against their involvement in the development of FD phenotypic manifestations.

AB - Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene. Fabry disease (FD) is an X-linked lysosomal storage disorder with a heterogeneous spectrum of clinical manifestations that are caused by the deficiency of α-galactosidase A (α-Gal-A) activity. Although useful for diagnosis in males, enzyme activity is not a reliable biochemical marker in heterozygous females due to random X-chromosome inactivation, thus rendering DNA sequencing of the α-Gal-A gene, alpha-galactosidase gene (GLA), the most reliable test for the confirmation of diagnosis in females. The spectrum of GLA mutations is highly heterogeneous. Many polymorphic GLA variants have been described, but it is unclear if haplotypes formed by combinations of such variants correlate with FD, thus complicating molecular diagnosis in females with normal α-Gal-A activity. We tested 67 female probands with clinical manifestations that may be associated with FD and 110 control males with normal α-Gal-A activity. Five different combinations of GLA polymorphic variants were identified in 14 of the 67 females, whereas clearcut pathogenetic alterations, p.Met51Ile and p.Met290Leu, were identified in two cases. The latter has not been reported so far, and both mutant forms were found to be responsive to the pharmacological chaperone deoxygalactonojirimycin (DGJ; migalastat hydrochloride). Analysis of the male control population, as well as male relatives of a suspected FD female proband, permitted the identification of seven different GLA gene haplotypes in strong linkage disequilibrium. The identification of haplotypes in control males provides evidence against their involvement in the development of FD phenotypic manifestations.

KW - Fabry disease

KW - GLA gene variants

KW - Haplotypes

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=84856509177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856509177&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0004.2011.01689.x

DO - 10.1111/j.1399-0004.2011.01689.x

M3 - Article

C2 - 21517827

AN - SCOPUS:84856509177

VL - 81

SP - 224

EP - 233

JO - Clinical Genetics

JF - Clinical Genetics

SN - 0009-9163

IS - 3

ER -